INTRODUCTION
============

The pathomechanisms of ischemic stroke are complex. The blockade of cerebral blood flow and subsequent hypoxia leads to neuronal death through several mechanisms including energy failure, neuronal excitotoxicity, neuroinflammation, and apoptosis ([@b12-molce-39-4-337]; [@b14-molce-39-4-337]). During cerebral ischemia, the expression of numerous genes, which are those involved in cell cycle, immune response, and cell survival are dysregulated following neuronal injury, resulting in neuronal death and subsequent functional deficits ([@b34-molce-39-4-337]). The recent development of transcriptome analysis with mRNA microarrays had shed light on the molecular mechanisms of acute cerebral ischemia ([@b26-molce-39-4-337]; [@b29-molce-39-4-337]; [@b36-molce-39-4-337]). In addition to studying disease pathogeneses, transcriptome analysis is a powerful tool to elucidate the molecular mechanisms of candidate therapeutics ([@b23-molce-39-4-337]).

Mesenchymal stem cells (MSCs) are a promising cell source for the treatment of ischemic stroke. Intravenous administration of MSCs (IV-MSC) is safe and effective in animal stroke models ([@b9-molce-39-4-337]; [@b10-molce-39-4-337]; [@b15-molce-39-4-337]; [@b18-molce-39-4-337]; [@b42-molce-39-4-337]) and clinical cases ([@b5-molce-39-4-337]; [@b13-molce-39-4-337]; [@b22-molce-39-4-337]). Despite limited migration and a low engraftment rate to the injury site ([@b38-molce-39-4-337]; [@b42-molce-39-4-337]), systemic MSC administration can induce functional improvement in cerebral ischemia by paracrine mechanisms.

MSCs exert a strong immunomodulatory effect by reducing cytokine and chemokine activation and stimulating the production of growth factors that help the brain recover from tissue damage ([@b24-molce-39-4-337]). However, how MSC treatment alters gene expression in the host brain is unclear. To understand the effect of IV-MSC in cerebral ischemia, it is necessary to evaluate the whole-genome expression pattern in the host brain. In the present study, we performed transcriptome analyses with mRNA microarray in a rodent stroke model to investigate the therapeutic mechanisms of IV-MSC in cerebral ischemia.

MATERIALS AND METHODS
=====================

Ethics statement
----------------

The cells used in this study were derived from the umbilical cord (UC) of a single healthy donor at CHA Bundang Medical Center (Korea) with informed consent. This study was performed following the approval of an Institutional Review Board from CHA Bundang Medical Center for the use of human UC resource (IRB no.: BD2013-004D). All of the experimental animals were manipulated in accordance with the Institutional Animal Care and Use Committee of CHA University (IACUC No.: 130006).

MSC preparation
---------------

To isolate MSCs, the umbilical vessels were removed, and Wharton's jelly was sliced into 1--5 mm explants that were subsequently cultured in α-minimal essential medium (α-MEM; Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, USA), fibroblast growth factor 4 (FGF4), and heparin on culture plates. The medium was changed every 3 days, and MSC cell populations appeared as outgrowths from the UC fragments on day 6. After 15 days, the UC fragments were discarded, and the cells were passaged using TrypLE (Invitrogen) and expanded until they reached subconfluence (80--90%). The cells were incubated under hypoxic conditions (3% O~2~, 5% CO~2~, and 37°C). In the present study, cells were used in experiments at passage 7. To identify MSC immunophenotypes, we performed fluorescence-activated cell sorting analysis as described previously ([@b19-molce-39-4-337]). The cells expressed high levels of CD44 (99.94 ± 0.01%), CD73 (100 ± 0.01%), CD90 (99.85 ± 0.06%), and CD105 (99.96 ± 0.03%) but negligible expressions of CD31 (1.43 ± 0.16%), CD34 (0.48 ± 0.06%), CD45 (1.63 ± 0.25%), and human leukocyte antigen (HLA)-DR (0.86 ± 0.10%). The cells were differentiated into adipocytes, osteocytes, and chondrocytes according to a previously described method ([@b19-molce-39-4-337]).

Rodent stroke model and IV-MSC treatment
----------------------------------------

Male Sprague-Dawley rats weighing 270--300 g were subjected to a 90-min middle cerebral artery occlusion (MCAo) animal model ([@b25-molce-39-4-337]). Two hours after reperfusion, a total of 1 × 10^6^ MSCs mixed with 500 μl saline was infused into the tail vein over 5 minutes (MSC group). The sham group only received saline with the same volume. No profound bleeding occurred during treatment, and the vital signs of all rats remained stable. The total mortality rates were evaluated for 4 weeks after treatment.

Whole transcriptome analysis
----------------------------

At 72 h after MCAo, the ipsilateral hemisphere subjected to MCAo was used for mRNA microarray. RNA was isolated as quickly as possible (within 20 min) from rats without MCAo (normal group, n = 6), rats treated with 1 × 10^6^ IV-MSC (MSC group, n = 7), and rats treated with saline (sham group, n = 5) by homogenization with TRIzol® Reagent (Gibco) and RNeasy columns (Qiagen, Germany). For RNA quality, the optical density (OD) cutoff at a 260/280 nm ratio was \>1.8 using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA). One sample from the normal group and two from the sham group were discarded because of low total RNA volume and low RNA quality, respectively. Afterwards, microarray experiments were conducted using samples from five rats in the normal group, five rats in the sham group, and six rats in the MSC group. RNA labeling and purification were performed, and the samples were hybridized to Agilent rat mRNA microarray chips (SurePrint G3 Rat Gene Expression 8x60k, Agilent Technologies) according to the manufacturer's instructions. Each array was scanned using the Agilent Technologies G2600D SG12494263. Array data-exporting processing and analyses were performed using Agilent Feature Extraction software (v100.0.1.1). The data were filtered by flag A, log transformation, and quantile normalization. The data from the three groups were analyzed using one-way variance of analysis (ANOVA) with correction of false discovery rate (FDR), and data with corrected p-values \< 0.05 (FDR-*p* \< 0.05) were selected. Post hoc analysis using Tukey's honest significant difference (HSD) test was conducted for pair-wise comparison. A differentially expressed gene (DEG) was defined as a fold difference (FD) ≥ 1.5 and corrected *p* value (*p*) \< 0.05. Predicted pathway analysis for the significant probe list was performed using DAVID Bioinformatics Resource ver. 6.7 (<http://david.abcc.ncifcrf.gov>) by inputting DEGs from the microarray data. The significantly predicted signaling pathway was determined based on *p* \< 0.05 after correction of FDR. All data analyses and visualization of DEGs were conducted using R 3.0.1 ([www.r-project.org](www.r-project.org)).

Immunohistochemistry
--------------------

Rats were transcardially perfused with heparinized saline. Brains were fixed overnight in 4% formalin at room temperature and then transferred to 30% sucrose with shaking for 48 to 72 h at 4°C. The brains were frozen in O.C.T. compound (Sakura Finetek, Japan). Double immunofluorescence labeling was performed on free-floating 40 μm-thick sections. Sections were incubated in blocking solution (5% normal horse serum, Vector Laboratories, USA) in phosphate-buffered saline (PBS) containing 0.3% Triton X-100 (Sigma, USA) for 1 h at room temperature. For evaluation of microglial activation, immunohistochemistry was performed using anti-Iba1 antibody (rabbit polyclonal, 1:250; Wako Pure Chemical Industries, Japan). After washing in PBS, the brain sections were incubated with fluorescence-conjugated secondary antibodies: goat anti-mouse IgG-conjugated Alexa 488 and 555, goat anti-rabbit IgG-conjugated Alexa 488 and 555 (1:200; Molecular Probes, USA) for 2 h. All sections were counterstained with the nuclear marker 4′, 6-diamidine-2′-phenylindole dihydrochloride (DAPI, Roche, USA).

Functional tests and infarct size measurement
---------------------------------------------

Functional tests were conducted by independent investigators blinded to the treatment groups. The modified neurological severity score (mNSS) was calculated as previously described ([@b8-molce-39-4-337]). For functional tests, rats were trained under the same conditions three times a day for 3 consecutive days prior to MCAo induction to reduce inter-animal variations. Infarct size was compared 72 h after MCAo using 2,3,5 triphenyltetrazolium chloride (TTC) staining. The brain was removed, and 1 mm was cut from the frontal tip and immersed in a 2% TTC solution. Stained slices were fixed in phosphate-buffered 4% paraformaldehyde. The ischemic and total hemispheric areas of each section were traced and measured, and the values were summed from six serial coronal sections per brain. We estimated infarct size as a percentage of the intact contralateral hemisphere with the following equation: estimated infarct size (%) = (1 − \[area of remaining ipsilateral hemisphere/area of intact contralateral hemisphere\]) × 100. The areas of interest were measured using ImageJ software (National Institutes of Health, USA), and values were summed from six serial coronal sections per brain. Ischemic volumes were measured by independent investigators blinded to the treatments.

Statistical analysis
--------------------

Statistical analysis was performed using the Statistical Analysis System program (Enterprise 4.1; SAS Korea) and MedCalc statistical software (MedCalc software, ver. 11.6., Mariakerke, Belgium). Statistically significant differences between two groups for infarct size and immunohistochemical data were analyzed with Mann-Whitney U tests. Functional tests were analyzed with mixed ANOVAs. *p* \< 0.05 was considered significant, and all values are presented as means ± standard error of mean (SEM). The statistical analysis of microarray data was previously described in the whole transcriptome analysis section.

RESULTS
=======

Genomic profiling changes in the ischemic brain after IV-MSC treatment
----------------------------------------------------------------------

We performed mRNA microarray-based whole transcriptome analyses on brain tissue 72 h after MCAo and compared normal (n = 5), sham (n = 5), and MSC (n = 6) groups. The 2D-multidimensional scaling (MDS) plot ([Fig. 1A](#f1-molce-39-4-337){ref-type="fig"}) shows a homogeneous genomic pattern in the normal group. Conversely, the sham and MSC groups exhibited wider plot distributions compared to the normal group, but a distinct plot distribution was detected between the sham and MSC groups. Of the 30,367 probes in the microarray, 19,035 were detected from the brain tissues used in this study. Among these, 5,414 probes were selected for FDR-*p* \< 0.05. After further selection of genes with FD ≥ 1.5 found at least in one tested group, we selected a total of 857 probes as DEGs (FD ≥ 1.5, FDR-*p* \< 0.05) ([Fig. 1B](#f1-molce-39-4-337){ref-type="fig"}). In a post hoc comparison between the sham and normal groups, a total of 857 DEGs were detected ([Fig. 1C](#f1-molce-39-4-337){ref-type="fig"}). In the sham group, most DEGs (680 of 857 transcripts, 79.3%) were upregulated compared to the normal group. The number of DEGs between the MSC and normal groups (118 DEGs) was much smaller than those between the sham and normal groups (857 DEGs) ([Fig. 1C](#f1-molce-39-4-337){ref-type="fig"}). The DEGs among the three groups are listed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. In a post hoc comparison between the MSC and sham groups, a total of 218 transcripts were differentially expressed, and most of them (175/218 DEGs, 80.2%) were downregulated in the MSC group compared to the sham group ([Fig. 1C](#f1-molce-39-4-337){ref-type="fig"}). The list of DEGs between the MSC and sham groups is presented in [Supplementary Table S2](#SD1){ref-type="supplementary-material"}. A dot-plot of gene expression for all DEGs shows that the extent of gene expression in the MSC group was relatively low compared to the sham group ([Fig. 1D](#f1-molce-39-4-337){ref-type="fig"}). For DEGs with FD ≥ 2 between the MSC and sham groups, the expressions of 30/38 (78.9%) transcripts in the MSC group were relatively reduced compared to those in the sham group ([Fig. 2](#f2-molce-39-4-337){ref-type="fig"}). These findings indicate that the expressions of numerous genes are changed (most are upregulated) in the host brain after cerebral ischemia, and IV-MSC attenuates the extent of postischemic genomic alterations in the ischemic brain.

We next performed predicted pathway analysis with DAVID software by inputting 857 DEGs between the normal and sham groups ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}) and 218 DEGs between the MSC and sham groups ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). For the first comparison, 10 pathways were predicted (corrected *p* \< 0.05, [Table 1](#t1-molce-39-4-337){ref-type="table"}). Most were related to inflammation, such as antigen-mediated immune response, pattern recognition immune response, and cytokine and chemokine signaling. In the comparison between the MSC and sham groups, three pathways were predicted: cell cycle, systemic lupus erythematosus (SLE), and Fc-gamma receptor (FcγR)-mediated phagocytosis (corrected *p* \< 0.05, [Table 2](#t2-molce-39-4-337){ref-type="table"}). Interestingly, most of the genes that were upregulated in the sham group compared to the normal group were downregulated in the MSC group compared to sham groups. These findings suggest that cerebral ischemia activates multiple signaling pathways mainly involved in inflammation and cell cycle-related signaling pathways, and IV-MSC partially attenuates the aberrant activation.

Inflammation in the ischemic brain after IV-MSC
-----------------------------------------------

As inflammation-related gene alterations are obvious following IV-MSC, we performed immunohistochemistry with the Iba-1 antibody to compare the extent of postischemic inflammation between the MSC (n = 4) and sham (n = 4) groups. In the sham group, numerous Iba-1^+^ cells were detected in peri-infarct areas of the ischemic brain 72 h after MCAo induction ([Fig. 3A](#f3-molce-39-4-337){ref-type="fig"}). In the MSC group, there were fewer Iba-1^+^ cells than in the sham group (37.9 ± 2.2% vs. 49.8 ± 3.2%, respectively; *p* = 0.01; [Fig. 3B](#f3-molce-39-4-337){ref-type="fig"}). These finding suggest that IV-MSC attenuates postischemic inflammation by reducing the number of activated immune cells in the ischemic brain.

Infarct size and functional deficits in MCAo rats after IV-MSC
--------------------------------------------------------------

We compared infarct sizes 72 h after MCAo using TTC staining. The mean infarct size was significantly smaller in the MSC group (MSC group vs. sham group: 29.4 ± 1.9% vs. 37.1 ± 1.4%, *p* = 0.003, both n = 7; [Fig. 4A](#f4-molce-39-4-337){ref-type="fig"}).

We next compared behavioral deficits assessed with the mNSS test for 4 weeks between the MSC (n = 6) and sham (n = 6) groups. Compared to sham animals, the MSC group showed a significant improvement in mNSS score from 14 to 28 days after MCAo ([Fig. 4B](#f4-molce-39-4-337){ref-type="fig"}). There was no difference in overall mortality between the two groups (*p* = 0.90). Our findings suggest that IV-MSC is neuroprotective during the acute phase of cerebral ischemia, which promotes subsequent functional recovery.

DISCUSSION
==========

In the present study, we performed transcriptome analyses to investigate the therapeutic mechanism of IV-MSC in a rodent stroke model. The mRNA microarray results revealed that the expressions of numerous genes are changed in the postischemic brain, with most upregulated. Many dysregulated genes are related to inflammation and cell cycle. Notably, bioinformatics analysis revealed that IV-MSC attenuated the aberrant activation of immune response- and cell cycle-related signaling pathways following ischemia. Consistent with previous microarray studies ([@b26-molce-39-4-337]; [@b29-molce-39-4-337]; [@b36-molce-39-4-337]), we found that the expressions of numerous genes related to inflammation and the cell cycle were altered in the ischemic brain. In response to ischemia, microglia and peripheral macrophages are activated and release pro-inflammatory cytokines (e.g., interleukins and tumor necrosis factors) that upregulate the expression of adhesion molecules on endothelial cells. Leukocytes and platelets promote the transmigration of circulating immune cells into the brain parenchyma. Activated chemokines and their receptors recruit bone marrow-derived mononuclear cells and endothelial progenitors to the ischemic lesion. Our microarray results showed that cerebral ischemia altered the expression of numerous genes encoding cytokines (e.g., tumor necrosis factor \[TNF\], interleukin \[IL\]-18, etc.), cytokine receptors (e.g., TNF receptor superfamily, IL-4, IL-10, IL-13 receptors, etc.), adhesion molecules (intercellular adhesion molecule \[ICAM\], alpha and beta integrins, etc.), chemokines (e.g., chemokine \[C-C motif\] ligand \[CCL\]6, CCL9, CCL13, chemokine \[C-X-C motif\] ligand \[CXCL\]10, C-C chemokine receptor \[CCR\]5, chemokine \[C-X3-C motif\] ligand 1 \[Cx3CL1\], etc.), and chemokine receptors (e.g., chemokine \[C-X-C motif\] receptor \[CXCR\]-4), pattern-recognition receptors \[Toll-like receptor (TLR)\]2, TLR4) and their signaling pathways (e.g., myeloid differentiation primary response 88 \[MYD88\], interferon regulatory factor 5 \[IRF5\], mitogen-activated protein kinase \[MAPK\], etc.) ([Table 1](#t1-molce-39-4-337){ref-type="table"}), most of which have been associated with stroke-related neuroinflammation ([@b14-molce-39-4-337]). The mRNA microarray findings showed that IV-MSC normalized the aberrant ischemia-induced expression of genes related to cytokines, chemokines, and their receptors. Furthermore, immunohistochemical analyses revealed that IV-MSC reduced the numbers of Iba-1^+^ cells in the ischemic brain. Accumulating evidence suggests that MSCs have a strong immune-modulating property. MSCs attenuate postischemic inflammation in rats ([@b42-molce-39-4-337]) by reducing pro-inflammatory cytokine activation (e.g., IL-1, TNF-α, or INF-γ) or enhancing anti-inflammatory cytokine expression (e.g., transforming growth factor-beta \[TGF-β\] and IL-10) ([@b11-molce-39-4-337]; [@b21-molce-39-4-337]; [@b27-molce-39-4-337]). MSCs also induce macrophage phenotype in the milieu of excessive inflammation, with pro-inflammatory M1 subtype polarizing toward the anti-inflammatory M2 subtype ([@b7-molce-39-4-337]). Based on the present findings, we propose that IV-MSC normalizes the aberrant expression of neuroinflammation-related genes following cerebral ischemia.

Interestingly, the pathway analysis predicted that IV-MSC strongly ameliorated the antigen-mediated immune response in cerebral ischemia (e.g., SLE and FcγR-mediated phagocytosis signaling pathways). Cerebral ischemia activates both humoral and cell-mediated immunity in response to the presentation of tissue antigens such as myelin basic protein and related peptides that were previously veiled by the blood-brain barrier in the central nervous system (CNS). In response to CNS antigen presentation, circulating T lymphocytes become sensitized and infiltrate the ischemic brain, eventually leading to neuroinflammation ([@b2-molce-39-4-337]; [@b16-molce-39-4-337]; [@b33-molce-39-4-337]; [@b40-molce-39-4-337]).

FcγRs are widely expressed in microglia in the CNS, ([@b37-molce-39-4-337]) and recent studies have shown the pivotal role of FcγR in neuronal injury in an animal model of stroke. FcγR−/− mice exhibit reduced mortality and smaller infarct size, presumably due to less microglial activation and circulating lymphocyte infiltration compared to wild-type mice ([@b20-molce-39-4-337]). IV immunoglobulin markedly reduces mortality and infarct size by 50% in a rodent stroke model ([@b3-molce-39-4-337]), and these effects are partially mediated by preventing FcγR-mediated phagocytosis of antigen-bearing target cells and antibody-dependent cell mediated cytotoxicity ([@b6-molce-39-4-337]; [@b32-molce-39-4-337]). MSC reduces the antigen-mediated immune response by suppressing cytotoxic T cells or enhancing the effect of regulatory T cells through the release of prostaglandin E2 and indoleamine 2,3-dioxygenase in vitro ([@b1-molce-39-4-337]). The therapeutic effect of MSC on antigen-mediated immune response has been demonstrated in animal models of multiple sclerosis ([@b41-molce-39-4-337]), rheumatoid arthritis ([@b4-molce-39-4-337]), graft-versus-host diseases, and SLE ([@b35-molce-39-4-337]). Although further studies are needed, our microarray analysis results suggest that attenuation of the antigen-mediated immune response in the ischemic brain is an important therapeutic mechanism of IV-MSC in the setting of cerebral ischemia.

Another interesting finding of our study is that cerebral ischemia alters the expression of cell cycle-related genes and these changes are ameliorated by IV-MSC. Previous reports support the critical role of cell cycle regulation in neuronal death following brain injury ([@b31-molce-39-4-337]). Hypoxia induces the expression of major cell cycle regulators such as cyclin D1, cyclin-dependent kinase (Cdk) 2, and E2F transcription factor 1 (E2F1) in oxygen-glucose deprived neurons ([@b17-molce-39-4-337]), implying that inappropriate activation of cell cycle machinery in differentiated neurons may elicit ischemic neuronal death. In an in vivo stroke model, expression levels of Cdk4 and cyclin D1 complex are altered following stroke ([@b30-molce-39-4-337]), and treatment with their inhibitors has a neuroprotective effect in animal models of cerebral ischemia ([@b28-molce-39-4-337]; [@b39-molce-39-4-337]). Our results suggest that IV-MSC attenuates the aberrant activation of cell cycle-related genes, thus preventing neuronal cell death. As a result, IV-MSC can reduce infarct size and promote functional improvement in a rodent stroke model.

Our study has several limitations, and further studies are needed to clarify the therapeutic mechanisms of IV-MSC in cerebral ischemia. Firstly, since our microarray analysis was conducted at a single time point (72 h after cerebral ischemia), we cannot reach a firm conclusion on therapeutic mechanisms of IV-MSC over time. As gene expression is dynamically altered at different time points after stroke, serial evaluation of gene expression changes is needed. Despite this shortcoming, our results still provide valuable information regarding the molecular changes in response to ischemia and the effect of IV-MSCs at the acute phase (72 h) of cerebral ischemia, since brain injury is usually most extensive in the first several days after cerebral ischemia ([@b14-molce-39-4-337]). Secondly, polymerase chain reaction-based analyses of individual DEGs should be performed to validate the microarray analysis results. Finally, our proposed therapeutic mechanism of IV-MSC in cerebral ischemia is dependent on bioinformatics analysis. We suggest that molecular changes following cerebral ischemia and IV-MSC are not dependent on individual gene expression; rather, they are due to multiple, complex genomic alterations. The present study focused on the overall genomic pattern rather than the functional mechanisms of single genes.

In conclusion, transcriptome analyses revealed that IV-MSC attenuated the extent of genomic alterations in the postischemic brain. Amelioration of dysregulated inflammation- and cell cycle-related gene expression in the host brain underlies the beneficial effects of IV-MSC in cerebral ischemia. Our study provides valuable information regarding the molecular therapeutic mechanism of IV-MSC in cerebral ischemia.

Note: Supplementary information is available on the Molecules and Cells website ([www.molcells.org](www.molcells.org)).

This study was supported by grants from the Basic Science Research Program (2011-0021344) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and Technology, the Next-Generation BioGreen 21 Program (No. PJ010002012014), the Rural Development Administration, and the Korea Healthcare Technology R&D project (HC14C3297) of the Ministry for Health, Welfare & Family Affairs, Republic of Korea.

![Genomic profiling in the rat brain after cerebral ischemia and IV-MSC treatment. (A) 2D-multidimensional scaling (MDS) plot in the normal (NL group, red circles), MCAo (sham group, green circles), and IV-MSC (MSC group, blue circles) rats. (B) Heat-map of differentially expressed genes (DEGs) in the normal (NL), sham, and MSC groups. (C) Numbers of DEGs according to the threshold of fold difference (FD ≥ 1.5 or FD ≥ 2.0) in expressions between the normal (NL), sham, and MSC groups. (D) Dot-plot showing the FD of the expression of individual DEGs (n = 857) in the sham (red dots) and MSC (dark-blue dots) groups compared to the normal group.](molce-39-4-337f1){#f1-molce-39-4-337}

![List of DEGs with FD ≥ 2 between the sham and MSC groups. The x-axis represents the relative FD of gene expression between the MSC and sham groups. The full name of individual genes are described in [Supplementary Table S2](#SD1){ref-type="supplementary-material"}.](molce-39-4-337f2){#f2-molce-39-4-337}

![Microglial activation changes in the postischemic brain after IV-MSC in MCAo rats. (A) Confocal microscopy for Iba-1 immunohistochemistry in brain sections from the sham (n = 4) and MSC (n = 4) groups. The right panel represents the brain area indicated by the yellow dashed box in the left panel. Scale bar, 20 μm. A nuclear marker, 4′, 6-diamidine-29-phenylindole dihydrochloride (DAPI, blue color) was used for counterstaining. (B) Graph showing the percentage of Iba-1^+^ to DAPI^+^ cells in the peri-infarct area of brains of the sham and MSC groups. ^\*^*p* \< 0.05 with Mann-Whitney U test.](molce-39-4-337f3){#f3-molce-39-4-337}

![Changes in infarct size and functional scores between the sham and MSC groups. (A) Measurement of infarct size 72 h after MCAo using 2,3,5-triphenyltetrazolium chloride (TTC) staining in the sham (n = 7) and MSC (n = 7) groups. ^\*^*p* \< 0.05 with Mann-Whitney U test. (B) mNSS scores between the sham (n = 6) and MSC (n = 6) groups. The 'pre' represents 1 day prior to MCAo induction. ^\*^*p* \< 0.05 with mixed ANOVA test.](molce-39-4-337f4){#f4-molce-39-4-337}

###### 

List of predicted signaling pathways for differentially expressed genes between the sham and normal groups

  Pathway                                     Count   \%     *p*        Corrected *p[^a^](#tfn1-molce-39-4-337){ref-type="table-fn"}*   FE     Genes
  ------------------------------------------- ------- ------ ---------- --------------------------------------------------------------- ------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Systemic lupus erythematosus                17      2.55   5.51E-06   7.82E-04                                                        3.85   Tnf, C6, Hist1h2ail, LOC498276, Hist2h3c2, RT1-DMa, C1r, C1s, Cd40, RT1-DMb, C1qc, C1qa, C1qb, Fcgr2b, Hist2h2ac, Fcgr1a, Fcgr2a, C2, Fcgr3a
  Toll-like receptor signaling pathway        15      2.25   9.99E-05   7.07E-03                                                        3.40   Ccl3, Tnf, Ly96, Tlr2, Tlr4, *Mapk11*, Cd40, Tlr6, Cxcl10, *Fos*, Myd88, Irf5, Map3k8, Cd14, Spp1
  Complement and coagulation cascades         13      1.95   1.21E-04   5.71E-03                                                        3.79   A2m, C5ar1, C6, C1r, Serping1, C1s, C1qc, C1qa, Vwf, C1qb, Cfh, C2, Cfd
  Natural killer cell mediated cytotoxicity   15      2.25   3.14E-04   1.11E-02                                                        3.06   Icam1, Ptpn6, Tnf, Itgb2, Hcst, Rac2, Fcgr2b, Plgc2, Fcer1g, Shc1, Fcgr2a, Fcgr3a, Ifngr1, Tyrobp, Lcp2, Syk
  Cell cycle                                  17      2.55   3.73E-04   1.05E-02                                                        2.75   LOC298795, Ttk, Pkmyt1, Cdk6, Chek1, Cdc20, Sfn, Mcm2, Pttg1, Mcm3, Mcm4, Tgfb1, Mcm6, Ccnd1, Plk1, Bub1, Ccna2, Myc
  MAPK signaling pathway                      27      4.05   4.88E-04   1.15E-02                                                        2.07   Tnf, Hspa1b, Nfkb2, Tgfb1, Map3k6, Tnfrsf1a, *Fos, Bdnf*, Rac2, *Rasgrp1, Rasgrp2*, Map3k8, Rras, Myc, Fgf2, Ptpn7, Tgfbr2, *Nr4a1, Cacng3, Mapk11*, Flna, *Dusp5*, Pla2g4a, *Dusp1, Ntrk1*, Hspb1, Cd14
  Focal adhesion                              21      3.15   1.22E-03   2.44E-02                                                        2.20   Parvg, Tln1, Col4a1, Col3a1, Igf1, Itga4, Birc3, Flna, *Pak6*, Vwf, Ccnd1, Rac2, *Vegfa*, Col6a2, Rhoc, Shc1, Lamc1, *Col11a2*, Parva, Spp1, Fn1
  Hematopoietic cell lineage                  12      1.80   1.29E-03   2.27E-02                                                        3.14   *Sept5*, Tnf, Cd44, Cd8b, Fcgr1a, Il4ra, Anpep, Itga4, Cd1d1, Cd14, Csf2ra, Csf1r
  Chemokine signaling pathway                 19      2.85   1.58E-03   2.47E-02                                                        2.27   Adcy4, Ccl3, Fgr, Ncf1, Hck, Ccl9, Pf4, *Cx3cl1*, Stat3, Ccl6, Cxcl10, Ccr5, Rac2, Cxcr4, Cxcl16, *Rasgrp2*, Rhoc, Shc1, Jak3
  ECM-receptor interaction                    12      1.80   1.77E-03   2.48E-02                                                        3.02   *Sept5*, Vwf, Sdc1, Col4a1, Cd44, Col3a1, Col6a2, Lamc1, Itga4, *Col11a2*, Fn1, Spp1
  Cytokine-cytokine receptor interaction      20      3.00   3.26E-03   4.13E-02                                                        2.07   Ccl3, Tnf, Tnfrsf12a, Il18, Il4ra, Tgfbr2, Pf4, Cd40, Cx3cl1, Cxcl10, Tnfrsf1a, Tnfrsf1b, Ccr5, Cxcr4, Il10rb, Cxcl16, Il13ra1, Csf2ra, Ifngr1, Csf1r
  Leukocyte transendothelial migration        14      2.10   3.75E-03   4.35E-02                                                        2.48   Icam1, Ncf1, Ncf4, Sipa1, *Mapk11*, Itgb2, Itga4, Cldn14, Cyba, Rac2, Cxcr4, Plcg2, Rhoc, Msn
  Lysosome                                    14      2.10   4.36E-03   4.66E-02                                                        2.44   Tcirg1, Ctsz, Gusb, Lgmn, Napsa, Cd63, Ctsl1, Slc11a1, Ctsk, Cd68, Laptm5, Ctsd, Ctsc, Cln5

*p*-value after Benjamini-Hochberg correction

The full names of genes are described in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

The genes italicized denote downregulated genes in the sham group compared to the normal group.

ECM, extracellular matrix; FE, fold enrichment; MAPK, mitogen-activated protein kinase

###### 

List of predicted signaling pathways for differentially expressed genes between the MSC and sham groups

  Pathway                        Count   \%     *p*        Corrected *p*[^a^](#tfn5-molce-39-4-337){ref-type="table-fn"}   FE     Genes
  ------------------------------ ------- ------ ---------- --------------------------------------------------------------- ------ ------------------------------------------------------------------
  Cell cycle                     10      5.68   1.60E-05   1.23E-03                                                        6.52   *Plk1, Bub1, Pkmyt1, Ttk, Cdc20, Pttg1, Mcm2, Mcm3, Ccna2, Mcm6*
  Systemic lupus erythematosus   8       4.55   8.80E-05   3.38E-03                                                        7.31   *C1qb, Tnf, Fcgr2b, Fcgr1a, LOC498276, Hist1h2ail, Fcgr3a, C1qc*
  FcγR-mediated phagocytosis     7       3.98   5.93E-04   1.51E-02                                                        6.54   *Arpc1b, Fcgr2b, Rac2, Ncf1, Hck, Fcgr1a, LOC498276*

*p*-value after Benjamini-Hochberg correction

The full names of genes are described in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

The genes italicized denote downregulated genes in the MSC group compared to the sham group.

FE, fold enrichment; FcγR, Fc-gamma receptor

[^1]: These authors contributed equally to this work.
